卵巢癌顺铂耐药细胞模型中14-3-3蛋白的差异表达  

Differential expression of 14-3-3 proteins in platinum resistance ovarian cancer cell model

作　　者：王慧香[1] 翟建军[1] 王蕾[1] 侯丽娟[1] 孙燕[1] 

机构地区：[1]首都医科大学附属北京同仁医院妇产科,北京100176

出　　处：《中国实用妇科与产科杂志》2011年第7期538-540,共3页Chinese Journal of Practical Gynecology and Obstetrics

摘　　要：目的探讨卵巢癌顺铂化疗耐药模型中14-3-3蛋白的差异表达,为深入研究卵巢癌顺铂耐药机制提供理论依据。方法分别提取卵巢癌顺铂耐药和敏感细胞的蛋白质,应用差异凝胶电泳(DIGE),通过DecyderTM分析软件获得差异表达蛋白质点,进行基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF-MS)分析、鉴定。结果经过二维电泳技术分离,MALDI-TOF-MS成功鉴定出2个14-3-3蛋白亚型,即14-3-3σ和14-3-3ζ,在耐药细胞中表达分别上调31%和38%,t检验P值分别为0.0049和0.0032。结论差异蛋白14-3-3σ和14-3-3ζ的鉴定为探讨这类蛋白在卵巢癌顺铂耐药中的作用奠定了基础,并提供了候选治疗靶点。Objective To investigate the differential expression of 14-3-3 proteins in platinum resistance and platinum sensitive ovarian cancer cell clones. Methods The proteins of COC1 and COC1/DDP were separated by highly sensitive two-dimensional differential gel electrophoresis （2-D DIGE） coupled with Matrix-assisted laser desorption/ionization-time of flight （MALDI-TOF-MS） for the identification of protein differentially expressed in cisplatin sensitive and cisplatin resistance cell lines. Results We found a group of the distinct expressed proteins between COC1 and COC1/DDP. Among them, and 14-3 -3 ξwere the up regulated proteins （14-3-3σ up regulated 31%. Student＇s t-test;P = 0. 0049; 14-3-3ξ up regulated 38%. Student＇s t-test;P = 0. 0032）. Conclusions The differential expression of 14-3-3proteins in COC1/ DDP lays foundation for the research of ovarian cancer platinum resistance, and offers new therapy targets for them.

关 键 词：卵巢癌 耐药 14—3—3蛋白 

分 类 号：R737.31[医药卫生—肿瘤]